

# MECOM-associated syndrome: a heterogeneous inherited bone marrow failure syndrome with amegakaryocytic thrombocytopenia

Manuela Germeshausen,<sup>1</sup> Phil Ancliff,<sup>2</sup> Jaime Estrada,<sup>3</sup> Markus Metzler,<sup>4</sup> Eva Ponstingl,<sup>5</sup> Horst Rüttschle,<sup>5</sup> Dirk Schwabe,<sup>6</sup> Richard H. Scott,<sup>7</sup> Sule Unal,<sup>8</sup> Angela Wawer,<sup>9</sup> Bernward Zeller,<sup>10</sup> and Matthias Ballmaier<sup>1</sup>

<sup>1</sup>Central Research Facility Cell Sorting, Hannover Medical School, Hannover, Germany; <sup>2</sup>Haematology and Oncology Department, Great Ormond Street Hospital for Children, London, United Kingdom; <sup>3</sup>Pediatric Specialists of Texas, Methodist Healthcare System, San Antonio, TX; <sup>4</sup>Pediatric Oncology and Hematology, University Hospital Erlangen, Erlangen, Germany; <sup>5</sup>Pediatric Practice Horst Rüttschle, Mutterstadt, Germany; <sup>6</sup>Pediatric Oncology, Hematology and Hemostaseology, University Hospital Frankfurt, Frankfurt, Germany; <sup>7</sup>Clinical Genetics Department, Great Ormond Street Hospital for Children, London, United Kingdom; <sup>8</sup>Center for Fanconi Anemia and Inherited Bone Marrow Failure Syndromes, Hacettepe University, Ankara, Turkey; <sup>9</sup>Division of Pediatric Hematology/Oncology, Department of Pediatrics, Technische Universität München, Munich, Germany; and <sup>10</sup>Department of Pediatric and Adolescent Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway

## Key Points

- Germ line mutations in *MECOM* cause a heterogeneous bone marrow failure syndrome with congenital hypomegakaryocytic thrombocytopenia.
- *MECOM*-associated syndrome includes various organ malformations with variable penetrance, including radioulnar synostosis.

Heterozygous mutations in *MECOM* (MDS1 and EVI1 complex locus) have been reported to be causative of a rare association of congenital amegakaryocytic thrombocytopenia and radioulnar synostosis. Here we report on 12 patients with congenital hypomegakaryocytic thrombocytopenia caused by *MECOM* mutations (including 10 novel mutations). The mutations affected different functional domains of the EVI1 protein. The spectrum of phenotypes was much broader than initially reported for the first 3 patients; we found familial as well as sporadic cases, and the clinical spectrum ranged from isolated radioulnar synostosis with no or mild hematological involvement to severe bone marrow failure without obvious skeletal abnormality. The clinical picture included radioulnar synostosis, bone marrow failure, clinodactyly, cardiac and renal malformations, B-cell deficiency, and presenile hearing loss. No single clinical manifestation was detected in all patients affected by *MECOM* mutations. Radioulnar synostosis and B-cell deficiency were observed only in patients with mutations affecting a short region in the C-terminal zinc finger domain of EVI1. We propose the term *MECOM*-associated syndrome for this heterogeneous hereditary disease and inclusion of *MECOM* sequencing in the diagnostic workup of congenital bone marrow failure.

## Introduction

Inherited bone marrow failure syndromes (IBMFSs) are a heterogeneous group of rare diseases that are characterized by insufficient production of blood cells of single or multiple hematopoietic lineages.<sup>1</sup> The underlying genes can be specific for hematopoietic cells, and hence, the symptoms are restricted to hematopoiesis, as in congenital amegakaryocytic thrombocytopenia (CAMT; Mendelian Inheritance in Man [MIM] #604498) caused by mutations in *MPL*.<sup>2,3</sup> However, a majority of IBMFSs are caused by defects in genes involved in common cellular pathways, such as transcriptional regulation, telomere maintenance, DNA repair, and ribosome function. The BMF in these diseases is often associated with other somatic anomalies that can be specific for particular diseases.<sup>1</sup>

The rare association of proximal radioulnar synostosis (RUS) with congenital amegakaryocytic thrombocytopenia (AT [this abbreviation is used for the hematological phenotype to distinguish it from the disease CAMT caused by mutations in *MPL*]) progressing to pancytopenia was first described in 3 patients from 2 families

and was attributed to a heterozygous variant in the homeobox gene *HOXA11* (RUSAT1; MIM #605432).<sup>4,5</sup> No other patients with pathogenic *HOXA11* variants have been reported since this first description.

In 2015, Niihori et al<sup>6</sup> identified heterozygous mutations in *MECOM* (*MDS1* and *EVI1* complex locus) in 3 unrelated patients with RUS and AT (RUSAT2; MIM #616738). Recently, 2 other patients with RUSAT2 were described,<sup>7,8</sup> and Bluteau et al<sup>9</sup> identified 6 patients with *MECOM* mutations in a large cohort of patients with IBMFSs (supplemental Table 1).

Here we report on 12 patients with AT caused by germ line mutations in *MECOM*, including 10 novel mutations. We found familial as well as sporadic cases; the clinical spectrum ranged from isolated RUS with no or mild hematological involvement to severe BMF without obvious skeletal abnormalities. The clinical picture can also include RUS, clinodactyly, cardiac and renal malformations, B-cell deficiency, and presenile hearing loss. We propose considering the different disease patterns as manifestations of a *MECOM*-associated syndrome, with RUSAT2 as a subgroup.

## Patients and methods

Patients suspected to have CAMT, but without mutations in the *MPL* gene, and patients with suspected hereditary thrombocytopenia were analyzed for mutations in *HOXA11* and *MECOM*. Patient material and clinical data were provided after informed consent. The study was approved by the local ethics committee.

## Sequencing of *MECOM*, *HOXA11*, *MPL*, and *TERC* genes

Genomic DNA was extracted from leukocytes, and mutational analyses were performed using Sanger sequencing with standard techniques. Primers for *MPL*, *HOXA11*, *TERC*, and *MECOM* were used as published previously.<sup>2,6,10,11</sup> Numbering of *MECOM* exons and designation of mutations refer to *MECOM* transcript variant 3 (NM\_001105078.3) unless otherwise specified.

## Evaluation of pathogenicity

Sequence variants were assessed for their pathogenicity according to a consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology using several types of variant evidence (eg, computational, functional, segregation, population data).<sup>12,13</sup> Different computational algorithms were used for prediction of the effect of *MECOM* mutations on protein function: PROVEAN (Protein Variation Effect Analyzer),<sup>14</sup> SIFT (Sorting Intolerant From Tolerant),<sup>15</sup> Polyphen2,<sup>16</sup> and MutationTaster.<sup>17</sup>

## Flow cytometric analyses

The staining of hematopoietic progenitors in fresh BM or frozen BM mononuclear cells (MNCs) was performed as described previously.<sup>18</sup> Peripheral blood leukocyte subsets in fresh blood or frozen MNCs were analyzed with the following antibodies (all BioLegend, San Diego, CA): CD3 FITC (OKT3), CD14 AF700 (63D3), CD16 PECy7 (3G8), CD19 PE (HIB19), CD45 PerCPCy5.5 (2D1), and CD56 APCCy7 (HCD56).

## Thrombopoietin plasma levels

Thrombopoietin (THPO) plasma levels were determined using a commercial enzyme-linked immunosorbent assay kit (Quantikine; R&D Systems, Minneapolis, MN).

## Results

### Sequencing

We analyzed DNA from 151 patients whose material had been sent to us for molecular confirmation of CAMT in which we had not found any *MPL* mutations. *MECOM* variants were found in 20 (Table 1; Figure 1). In 6 patients (P1-P6), we found heterozygous *MECOM* mutations in the previously described small region coding for the eighth zinc finger, including 1 missense mutation previously reported for RUSAT2 patients (P5, P6),<sup>6,7,9</sup> 3 novel missense mutations (P1-P3), and 1 novel frameshift deletion (P4). Seven more patients were identified with heterozygous mutations (7 novel) in other regions of the *MECOM* gene (P7-P13). Rare single-nucleotide variations reported in public databases were identified in 7 other patients (P14-P20). All patients tested (n = 19; P1-P11, P13-P20) had no alterations in *TERC* excluding a cooperative effect of this gene, which is located in the immediate vicinity of *MECOM*.

### Evaluation of pathogenicity

We assessed the probability of pathogenicity of the variants found in the patients by analyzing the data from public databases, family analyses, and prediction algorithms<sup>12,13</sup> (Table 1; supplemental Table 2).

**Population data.** Mutations found in patients P1 to P13 were not listed in publicly available population databases (including ExAc, covering >60 000 exomes), supporting a pathogenetic significance. Rare variants listed in the ExAc database were found in patients P14 to P19. The allele frequencies of variations observed in patients P16 to P19 in our cohort were in the range of expectance from the ExAc data, arguing for a benign interpretation. In contrast, the allele frequency of the variation found in P14 and P15 in our cohort was significantly higher than expected from the frequency reported in ExAc (2 of 298 vs 45 of 12 1406; Fisher's exact test  $P < .01$ ), suggesting pathogenic involvement.

**Family analyses.** We were able to analyze DNA from family members for 11 of the patients; segregation of the phenotype with the mutation was observed in 3 families (P1, P2, P10), and de novo mutations were found in 4 patients (P3-P5, P9). For 4 patients, we observed the mutation in an unaffected family member (P8, P13, P15, P16).

**In silico analyses.** Analysis of the mutations using different algorithms revealed deleterious and disease-causing effects for all missense mutations in patients P1, P2, P3, P5, P6, and P12. Mutations in patients P1 to P6 affected the previously described highly conserved region of the eighth zinc finger motif; the mutation in P12 affected the adjacent ninth zinc finger motif (Figure 1). Mutations in P7 to P11 were all predicted to lead to a truncated protein. The mutation in P13 and the alterations in P14 to P20, which have been listed in public databases as rare polymorphisms, were predicted to have less effect on *MECOM* function (Table 1).

On the basis of information (Table 1; supplemental Table 2), 11 of the 16 different variations could be judged as pathogenic (n = 3) or likely pathogenic (n = 8; supposed certainty >90%<sup>12</sup>). For 4 variations, the significance remains uncertain because of a lack of data or because of contradictory criteria. Only the variation rs116535717 found in patients P16 to P18 was judged as benign on the basis of the available data. For the further phenotypic analysis of the patients with *MECOM* mutations, we included patients P1 to P12 bearing mutations with a high likelihood of pathogenicity.


**Table 1. MECOM variations in patients with hypomegakaryocytic thrombocytopenia**

Patient	Genomic variation (GRCh38,p7) variation (refSNP)	Transcript variant 3 (NM_001105078.3)		PROVEAN <sup>14</sup> prediction/score (cutoff -2.5)	SIFT <sup>15</sup> prediction/ score (cutoff 0.05)	PolyPhen-2 <sup>16</sup> prediction/score	MutationTaster <sup>17</sup> prediction/ probability	Found in ExAC or 1000G (MAF/MAC)	Pathogenicity (ACMG Consensus <sup>12,13</sup> )
		E/I No.	CDS/protein Type						
P1	chr3:g.169100919G>A	E11	c.2251C>T p.His751Tyr	Missense Deleterious -5.48	Damaging 0.000	Probably damaging 1.000	Disease causing 1.000	N	Likely pathogenic
P2	chr3:g.169100894T>A	E11	c.2276A>T p.Gln759Leu	Missense Deleterious -6.27	Damaging 0.001	Probably damaging 0.996	Disease causing 1.000	N	Likely pathogenic
P3	chr3:g.169100892G>A	E11	c.2278C>T p.Pro760Ser	Missense Deleterious -6.97	Damaging 0.006	Probably damaging 1.000	Disease causing 1.000	N	Likely pathogenic
P4	Chr3:g.169100962_169100963delC	E11	c.2208-1_2208delGA p.Arg736Ser is*13	Deletion frameshift	NA	NA	Disease causing 1.000	N	Pathogenic
P5/P6	chr3:g.169100922G>A (rs864309724)	E11	c.2248C>T p.Arg750Trp	Missense Deleterious -6.98	Damaging 0.000	Probably damaging 1.000	Disease causing 1.000	N	Pathogenic
P7	chr3:g.169093016G>A	E13	c.2542C>T p.Arg648Ter	Nonsense	NA	NA	Disease causing 1.000	N	Likely pathogenic
P8	chr3:g.169128041G>T	E4	c.69C>A p.Cys23Ter	Nonsense	NA	NA	Disease causing 1.000	N	Likely pathogenic
P9	chr3:g.169095075C>G	I12	c.2455+1G>C Loss of splice site	Splice site mutation	NA	NA	Disease causing 1.000	N	Pathogenic
P10	chr3:g.169116194G>A	E7	c.1114C>T p.Gln372Ter	Nonsense	NA	NA	Disease causing 1.000	N	Likely pathogenic
P11	Chr3:g.169095111_169095112insT	E12	c.2419_2420insA p.Arg607Lys is*7	Insertion frameshift	NA	NA	Disease causing 1.000	N	Likely pathogenic
P12	chr3:g.169095235A>G	E12	c.2296T>C p.Cys766Arg	Missense	Deleterious -10.12	Possibly damaging 0.845	Disease causing 1.000	N	Likely pathogenic
P13	chr3:g.169116402G>C	E7	c.906C>G p.Ser302Arg	Missense	Neutral -1.53	Probably damaging 0.999	Disease causing 1.000	N	Uncertain significance
P14/P15	chr3:g.169095082T>C (rs200049869)	E12	c.2449A>G p.Met817Val	Missense	Neutral 0.16	Benign 0.000	Disease causing 0.949	ExAc: Y (0.0004/45) 1000G: N	Uncertain significance
P16/ P17/ P18	chr3:g.169143748C>A (rs116535717)	E2	c.-105G>T ? ?	5'UTR	NA	NA	Disease causing 0.529	ExAc: Y (0.0047/561) 1000G: Y (0.0068/34)	Benign
P19	chr3:g.169122674T>C (rs34896995)	E5	c.320A>G p.Gln107Arg	Missense	Damaging 0.030	Possibly damaging 0.946	Disease causing 1.000	ExAc: (0.0026/319) 1000G: (0.0010/5)	Uncertain significance
P20	chr3:g.169145034T>C (rs370795924)	E5	5'UTR	5'UTR	NA	NA	Disease causing 1.000	N (1 individual <sup>48</sup> )	Uncertain significance
P16/ P17/ P18	chr3:g.169143748C>A (rs116535717)	E3*	c.88G>T p.Ala30Ser*	Missense*	Neutral -1.11	Possibly damaging 0.548	Disease causing 0.529	ExAc: 561/120542 1000G: 34	Benign

The table lists all mutations found in this study, together with the results from different algorithms analyzing the potential effects on protein structure and function (bold font indicates novel mutations). The last column lists the results of the classification of the mutations using the recommendations of the American College of Medical Genetics and the Association for Molecular Pathology (supplemental Table 2).<sup>12</sup> Only patients P1 to P12 with mutations judged to be pathogenic or likely pathogenic were included in further phenotypic analysis.

ACMG, American College of Medical Genetics and Genomics; CDS, coding sequence; MAC, minor allele count; MAF, minor allele frequency; N, no; NA, not applicable; UTR, untranslated region; Y, yes.

\*All designations in the table except for the last row refer to MECOM transcript variant 3 (NM\_001105078.3, NP\_001098548.2). Designations for transcript variant 1 (NM\_001105077.3, NP\_001098547.3) are added for mutation rs116535717, located in the 5'-UTR of transcript variant 3 (Figure 1).



**Figure 1. MECOM mutations in patients with congenital BMF and consequences for protein isoforms of MECOM.** Exon structure of the *MECOM* locus together with the main transcript variants are shown together with constitutive mutations in *MECOM* found in this study. The transcript variants use different start codons and alternatively spliced amino termini. Truncating mutations are labeled in red, missense mutations in blue, and 5' untranslated region mutations in black. Patient identifiers for those affected by *RUSAT* are labeled in green. Pathogenic mutations (P1-P12) are labeled in full color; mutations of uncertain significance of pathogenicity or benign variations (P13-P20) are labeled in pale colors. Diamonds indicate nonsense mutations; triangles indicate frameshift mutations. AD, acidic domain; NLS, nuclear localization sequence; RD, repression domain; S, splice site mutation; ZF, zinc finger motif.

Clinical information about patients P13 to P20 is listed in supplemental Table 3.

### Patient phenotypes

**Patients with *RUSAT*.** P1, characterized by a novel heterozygous missense mutation affecting the same amino acid residue as a previously described mutation<sup>6</sup> (c.2251C>T, p.His751Tyr), was born with severe thrombocytopenia and bilateral *RUS*. There was a history of a similar malformation of the forearms in this family; the father of the patient, the paternal grandfather, and a paternal half-brother were all affected by a similar deformity of the forearms, leading to limited pronation and supination, which could be attributed to proximal *RUS* in the patient and his father (Figure 2A). No detailed information was available for the other family members. DNA from peripheral blood cells of P1's father revealed only a minor signal for the *MECOM* mutation that could have resulted from somatic mosaicism.

The family of P2 (c.2276A>T, p.Gln759Leu) presented after 2 unexplained intrauterine deaths. Postmortem analysis revealed hypocellular BM in both fetuses. The older brother of P2 suffered an unexplained neonatal stroke. Blood counts, coagulation studies, and marrow morphology were normal. P2 developed symptomatic AT, which progressed to pancytopenia and required hematopoietic stem-cell transplantation (HSCT). The mother, both children, and both stillborn fetuses had *RUS* (Figure 2B). P2 was also deaf. All members of the family affected with *RUS* carried the *MECOM* mutation.

In P3 and P4, *RUS* was diagnosed some years after birth. P3 (c.2278C>T, p.Pro760Ser) was born with severe pancytopenia, and a BM examination revealed a lack of megakaryocytes. Physical examination was inconspicuous. Pancytopenia was ameliorated


during the first weeks of life, and the child was temporarily lost to follow-up. At age 25 months, the patient presented with limited supination of the forearms and reduced extension of the elbow joint, hindering the protective arm movements during falling. *RUS* was diagnosed by radiography.

P4, characterized by a loss of splice acceptor site at the 5' border of exon 11 (c.2208-1\_2208delGA), postnatally presented with severe pancytopenia and severely hypoplastic BM. She underwent allogeneic HSCT with the preliminary diagnosis of CAMT. *RUS* was first detected at the age of 3 years by radiography.

Patient P12, with a missense mutation affecting the ninth zinc finger motif (c.2296T>C, p.Cys766Arg), presented at age 1 year with bilateral *RUS* and mild thrombocytopenia, which gradually progressed to pancytopenia and BMF.

**BMF without *RUS*.** In 2 patients (P5, P6) with severe congenital pancytopenia, we detected the mutation c.2248C>T (p.Arg750Trp) previously reported for 3 other patients with *RUSAT*.<sup>6,7,9</sup> Both were platelet and erythrocyte transfusion dependent from birth and experienced severe recurrent bacterial and fungal infections. Radiographs for upper extremities revealed no anomalies; *RUS* could be excluded in P5 (Figure 2C). P5 died as a result of catheter-related sepsis at the age of 8 months. Of the 3 elder sisters of P6, 1 presented with Pierre Robin sequence and another with craniosynostosis. P6 and another sister had no physical stigmata. The girl died after HSCT at the age of 5 months.

P7 to P11 had nonsense, frameshift, or loss of splice site mutations predicted to lead to termination of the *MECOM* protein (Table 1). These patients showed severe pancytopenia from birth or isolated



**Figure 2. Pedigrees and radiographs of upper limbs of patients P1, P2, and P5.** Pedigrees of the familial cases P1 (A) and P2 (B) showing the occurrence of RUS (left area black) and CAMT/congenital aplastic anemia (right area black); radiographs of the upper limbs demonstrating proximal RUS in family members (small symbols indicate stillborn fetuses). (C) Pedigree and radiograph of sporadic case P5; radiograph of the forearm of P5 in pronated state, ruling out RUS. Genotype is included for the analyzed individuals of the pedigrees. M, wild-type allele; m, mutated allele.

thrombocytopenia with rapid development of pancytopenia during the first weeks of life.

**Additional phenotypes observed in patients with MECOM-associated syndrome.** Besides BMF and RUS, other malformations were observed in some of the patients (Table 2). Skeletal anomalies other than RUS were mainly observed in the hands (clinodactyly or brachydactyly in patients P1, P3, P7, P9, P10, P12; Table 2). Malformations in other organ systems included congenital heart failure (P7: ventricular septal defect plus aortic coarctation; P8: ASD; P10: tetralogy of Fallot) and renal malformations (P4: cystic kidney with megaureter left and functional duplex kidney right; P5: mild bilateral renal calyceal dilatation). Congenital deafness was observed in 3 patients in this study (P2, P10, P12). Interestingly, the father of P10, from whom the *MECOM* mutation was inherited, was also affected by deafness.

Developmental anomalies in some of the patients may hint at hormonal disturbances. Precocious puberty was observed in P8, and gynecomastia in infancy (Tanner stage B3) occurred in P11.

Chromosome breakage analysis or G2-arrest analysis for diagnosis of Fanconi anemia revealed normal results for all patients. None of the patients showed typical symptoms of dyskeratosis congenita (eg, nail dystrophy, abnormal pigmentation, or leukoplakia)

### Analysis of hematopoietic progenitor cells and THPO plasma levels

Because *Evi1* has been reported to regulate *Mpl* expression in mice,<sup>19</sup> it has been speculated that the hematological phenotype of *MECOM* haploinsufficiency might be related to altered *MPL* expression on hematopoietic progenitors.<sup>20</sup> By means of flow cytometry, we were able to analyze hematopoietic progenitors in the BM of P1. We found a percentage of  $CD34^{+}$  in the total nucleated

cells of the BM; it was within the normal range (2.8%), but there was only a small population of  $CD34^{hi}CD38^{lo}$  progenitor cells, which may reflect an early exhaustion of early hematopoietic progenitors (0.06% of total nucleated cells and 2% of  $CD34^{+}$  cells; Figure 3A). Although rare, these  $CD34^{hi}CD38^{lo}$  cells showed a low but distinct *MPL* ( $CD110^{+}$ ) expression (Figure 3B), distinguishing them clearly from  $CD34^{hi}CD38^{lo}$  cells from patients with CAMT.<sup>18</sup> Retrospective analysis of cryopreserved BM MNCs from patients P3, P11, P15, and P18 showed normal *MPL* expression on early  $CD34^{hi}CD38^{lo}$  cells.

Plasma levels of THPO were exceptionally high in samples available from P1, P4, and P11, pointing to an advanced exhaustion of hematopoiesis (supplemental Table 4). Only a moderately elevated THPO level was seen in patient P8, which was not in accordance with the advanced state of BMF but which could have resulted from the long shipping time of the sample.

### Lymphocyte subpopulations


Some of the patients in this study experienced severe recurrent infections (P4, P5, P6), as reported earlier for other patients with RUSAT.<sup>21,22</sup> Clinical reevaluation revealed hypogammaglobinemia and B-cell deficiency in patients P4 and P5. For some of the patients, flow cytometric determination of lymphocyte subsets was initially performed during diagnostic workup; for others, we were able to analyze cryopreserved samples from the patients (Table 3). We found low absolute and/or relative numbers of B cells in the peripheral blood of patients P1, P3, P4, and P5, all with mutations affecting the eighth zinc finger. Relative and absolute B-cell numbers were below the 90% prediction range in P1 and P4. Interestingly, the father of P1, affected by RUS but not by thrombocytopenia, also showed low relative and absolute B-cell counts. For P5, absolute B-cell numbers were not available, but a severe B-cell deficiency was obvious in light of the severe pancytopenia and the B-cell percentage of 1% in

**Table 2. Clinical characteristics of patients with MECOM mutations with high certainty of pathogenicity**

Patient	Sex	Hematological course	HSCt (age in months)	RUS	Other skeletal malformations	Other malformations	Hearing	Other/remarks	Family history	MECOM mutation (transcript variant 3)
P1	M	Congenital TP and anemia, progressive BMF	MUD (11)	Y	Hypoplasia of middle and end phalanx D5	N	Normal		RUS in family members	c.2251C>T, p.His751Tyr
P2	M	Congenital TP, progressive BMF	First: MFD (8); second: MUD (21)	Y	N	N	Impaired (hearing aids)		RUS and RUSAT in family members	c.2276A>T, p.Gln759Leu
P3	M	Severely pancytopenic at birth but spontaneous amelioration during first weeks of life, persisting mild TP	N	Y	Clinodactyly D5, hypoplasia of middle phalanx D5	N	ND			c.2278C>T, p.Pro760Ser
P4	F	Congenital TP and anemia, progressive BMF	MUD (7)	Y	Toe malposition D2 bilateral	Cystic kidney (left), duplex kidney (right), urinary obstruction with megaureter (left)	Normal	Hypogammaglobulinemia	N	c.2208-1_2208delGA, loss of splice acceptor site
P5	F	Severe congenital pancytopenia, progressive BMF	Died as a result of sepsis before HSCT	N	N	Hepatomegaly and mild bilateral renal calyceal dilatation	ND	Severe infections, B-cell deficiency	N	c.2248C>T, p.Arg750Trp
P6	F	Severe congenital pancytopenia, extremely hypocellular BM	MUD (5), TRD	N	N	N	ND	Severe bacterial and fungal infections, GI bleeding	Healthy parents, 1 sister with Pierre Robin sequence, 1 sister with craniosynostosis	c.2248C>T, p.Arg750Trp
P7	M	Congenital TP and anemia, progressive BMF	MUD (4), TRD	N	Brachymesophalangy D5	Subpulmonary YSD, aortic coarctation	Normal			c.2542C>T, p.Arg848Ter
P8	F	Congenital TP and anemia, progressive BMF	UCB (3)	N	N	ASD, small cleft palate	ND	Precocious puberty, cognitive deficits		c.69C>A, p.Cys23Ter
P9	M	Fetal adrenal hemorrhage (w30) resulting from TP, fast progression to pancytopenia and BMF	MUD (10.5), TRD	N	Thumb under D2	N	Severe bacterial and fungal infections			c.2455+1G>C, loss of splice donor site
P10	M	Pancytopenia	MFD (156)	N	Floating elbow, clinodactyly D5	Tetralogy of Fallot	Congenital hearing loss		Niece with severe BMF (HSCT: MUD at age 8 mo); father hearing impaired	c.1114C>T, p.Gln372Ter
P11	F	Congenital TP, progressive BMF	MUD (16)	N	Hip dysplasia (left)	N	Inconspicuous	Gynecomastia in infancy (Tanner stage B3)	N	c.2419_2420insA, p.Arg807Kfs7
P12	M	Mild TP at age 1 y, progressive BMF	MUD (85)	Y	Clinodactyly D5, brachydactyly D1 and D2, small patellae	N	Bilateral deafness		N	c.2296T>C, p.Cys766Arg

HSCT outcome was positive unless otherwise indicated.

ASD, atrial septal defect; F, female; GI, gastrointestinal; M, male; MFD, matched family donor; MUD, matched unrelated donor; ND, no data; TP, thrombocytopenia; TRD, transplantation-related death; UCB, unrelated cord blood.



**Figure 3. Analysis of hematopoietic progenitors from P1.** Flow cytometric analysis of BM cells of patient P1 at age 2.3 months. Cells were stained with CD38-FITC, CD34-APC, CD110-PE (or PE-labeled isotype control), and 4',6-diamidino-2-phenylindole as a viability marker. Gated on viable nucleated cells (A) and on CD34<sup>+</sup>CD38<sup>lo</sup> cells (B). Red indicates isotype control; blue indicates CD110 (MPL).

the lymphocytes. P3 showed low absolute B-cell count at the age of 9 months; at age 7 years, B cells were within the normal range. This was in line with the amelioration of anemia and thrombocytopenia in this patient. In all patients with mutations in other regions of the *MECOM* gene, we found normal percentages of B cells in the lymphocytes.

## Discussion

The association of RUS and AT caused by mutations in *HOXA11* (*RUSAT1*) was first described by Thompson and Nguyen.<sup>4</sup> An association of RUS with late-onset progressive BMF was described earlier by Dokal et al.<sup>23</sup> As in the pedigrees with *HOXA11* variants, the skeletal defect segregated as an autosomal dominant trait and the hematological phenotype of progressive marrow failure showed a variable expression. Niihori et al<sup>6</sup> found mutations in *MECOM* in 3 sporadic cases of *RUSAT2* with early BMF, suggesting a specifically severe phenotype of *RUSAT2*. Recently, 2 other families with *RUSAT2* were described.<sup>7,8</sup> A study investigating germ line mutations in a group of 179 patients with IBMFS identified 6 more patients with *MECOM* mutations; interestingly, only 1 of them had RUS (supplemental Table 1).<sup>9</sup>

In this study, we report on 12 patients with yet unclassified AT from different families caused by mutations in *MECOM*. We found a continuous spectrum of clinical manifestations in the patients and affected relatives.

*MECOM* codes for a zinc finger transcription factor with important roles in normal development and oncogenesis. The *MECOM* locus encodes a number of differentially spliced transcripts yielding the MDS1, MDS1-EVI1, and EVI1 protein isoforms. From different animal models, it has become obvious that the physiological role of the gene lies in the regulation of embryonic development and regulation of hematopoietic stem-cell renewal.<sup>24-29</sup> Spatiotemporal expression patterns were observed during mouse embryonic development, with expression in the developing lung, heart, urogenital system, and emerging limb buds.<sup>30</sup> *MECOM* is involved in numerous rearrangements leading to overexpression or formation of fusion transcripts with *RUNX1* or *ETV6* in myeloid malignancies.<sup>31</sup>

The role of *MECOM* in human hematopoiesis is emphasized by the phenotype of the patients in this study; all patients were affected by thrombocytopenia, and most of them developed hypoplastic BM and pancytopenia. Our experiments, together with published data, strongly suggest an impaired maintenance of hematopoietic stem cells

as the reason; we were able to demonstrate a severe reduction of early CD34<sup>+</sup>CD38<sup>lo</sup> progenitors in the BM, which closely resembled the strong reduction of early hematopoietic cells in the BM of mice with a heterozygous deletion of *Evi1* exon 4.<sup>28</sup> Other experiments have suggested that *Evi1* expression leads to upregulation of stemness genes and enhanced survival.<sup>29</sup> The influence of *EVI1* expression on *MPL*, another important player in stem-cell regulation, is not clear. Whereas expression of *MPL* was positively correlated with that of *EVI1* in patients with acute myeloid leukemia,<sup>32</sup> *Evi1* repressed the expression of *Mpl* in a mouse model.<sup>19</sup> In our patients, we found highly elevated *THPO* plasma levels, which were in the range of those measured in patients with *CAMT*.<sup>2,33</sup> Nevertheless, *MPL* expression was detectable on CD34<sup>+</sup>CD38<sup>lo</sup> cells, making downregulation of *MPL* unlikely. The high *THPO* plasma levels can be explained by the marked loss of *MPL*-expressing cells in blood and BM.

A recent publication suggested *MECOM* as a candidate gene for hereditary hematological malignancies.<sup>8</sup> In a family with 4 members affected by *MECOM* mutations and RUS, 2 developed myelodysplastic syndrome at older ages (73 and 48 years). Although we did not observe any malignancies in our patients or relatives, a continuous disturbance of hematopoiesis in patients with mild hematologic phenotypes may account for a higher risk of malignant transformation.

Previous findings have suggested proximal RUS as a pathognomonic sign of *MECOM*-associated syndrome.<sup>6-8</sup> However, most of our patients (as well as those in the IBMFS study by Bluteau et al<sup>9</sup>) were not affected by RUS, including 2 patients bearing a mutation reported in the 3 patients with *RUSAT2*.<sup>6,7,9</sup> For a short time in embryonic development, the radius and ulna share a common perichondrium, and a perturbation of the process of segmentation by abnormal genetic or teratogenic factors can lead to a more or less distinct synostosis,<sup>34</sup> a fact which might explain the differences in the penetrance of this trait. *MECOM* is specifically expressed in the emerging limb buds in embryogenesis, but insufficient production seems to have no effect on bone development; skeletal abnormalities were not observed in any of the *Evi1* knockout models.<sup>35</sup> Furthermore, 2 patients with heteroinsufficiency of the *MECOM* gene resulting from deletion at chromosome 3q26 did not display RUS.<sup>20,36,37</sup> Niihori et al<sup>6</sup> suggested that the missense mutations identified in their study might act as gain-of-function or partial loss-of-function mutations rather than complete loss-of-function mutations. This hypothesis is supported by the fact that the only *MECOM*-associated skeletal malformation (polydactyly in the

**Table 3. Lymphocyte subpopulations in patients**

Patient	Age, mo	CD3 relative, % of lymphocytes (reference value <sup>49</sup> ; mean; 90% range)	CD3, $\mu\text{L}^{-1}$ (reference value <sup>50</sup> ; predicted; 90% range)	CD19, % of lymphocytes (reference value <sup>49</sup> ; mean; 90% range)	CD19, $\mu\text{L}^{-1}$ (reference value <sup>50</sup> ; predicted; 90% range)
P1	2.3	NA	NA	<b>5.5</b> (17; 8-33)	<b>356</b> (1589; 740-2574)
P1 father	480	89.6 (67; 50-91)	2292 (1373; 679-2214)	<b>3.72</b> (10; 4-28)	<b>95</b> (268; 125-434)
P3	8.7	72.2 (68; 49-95)	2203 (3845; 1906-6195)	17.7 (16; 4-54)	<b>540</b> (1446; 674-2343)
P3	87	77.3 (73; 55-97)	1640 (1734; 854-2794)	16.6 (12; 4-33)	362 (559; 260-905)
P4	2.7	95 (69; 49-97)	3469 (4274; 2121-6887)	<b>5</b> (17; 8-33)	<b>200</b> (1581; 736-2561)
P4	4.9	92 (69; 49-97)	10 326 (4107; 2038-6617)	<b>1</b> (17; 8-33)	<b>78</b> (1529; 712-2477)
P5	4.0	97 (69; 49-97)	NA	<b>1</b> (17; 8-33)	NA
P8	1.5	85.0 (70; 55-90)	NA	13.9 (14; 3-60)	NA
P11	9.5	60.7 (70; 56-87)	NA	37.4 (15; 3-77)	NA

Available data for T- and B-cell populations in patients from this study are listed together with age-matched reference values.<sup>49,50</sup> Bold font indicates values outside the 90% range. NA, not available.

forelimbs) in a mouse model was observed in mice with a dominant missense mutation in the C-terminal zinc finger domain of MECOM.<sup>38</sup> Our findings of diverse *MECOM* mutations leading to RUS, including the mutation in P4 leading to a complete loss of the carboxy terminus including the eighth zinc finger, support the hypothesis of a partial loss of function of the C-terminal zinc finger domain vs gain of function. RUS was observed only in patients with mutations affecting a small region including the eighth and ninth zinc finger motifs. Other skeletal anomalies in our group, like hypoplastic middle phalanges of the fifth digit (also described in patients with *RUSAT2*<sup>6</sup>) or hip dysplasia (also described in patients with *RUSAT1*<sup>5</sup> and *RUSAT2*<sup>7</sup>), were not necessarily associated with mutations in this region, but all affected the carboxy terminal part of the protein.

B-cell deficiency also seems to be a part of the clinical spectrum of MECOM-associated syndrome. In some of the patients, we saw B-cell deficiency that might have been causative of severe recurrent bacterial and fungal infections. A pancytopenia with total B-cell deficiency was also reported for a patient with a heterozygous deletion of 3q26, including the 3' part of *MECOM*.<sup>37</sup> It is not clear whether B-cell deficiency in MECOM-associated disease is due to a common stem-cell defect or to the specific involvement of MECOM in B-cell development. A specific role in B-cell development is suggested by the fact that a gene amplification of *MECOM* seems to play a role in persistent polyclonal binucleated B-cell lymphocytosis.<sup>39</sup> Furthermore, Mecom has been identified as 1 of the shared targets of Menin and MLL1 in murine hematopoietic stem cells and B cells, and hence, it seems to be involved in critical pathways for regulation of regenerative hematopoiesis and B-cell differentiation.<sup>40</sup> Additional studies in patients with *MECOM*-associated AT are necessary to establish a specific B-cell defect.

Two of our patients and 2 of the reported patients (supplemental Table 1) with *MECOM* mutations had renal phenotypes. MECOM has been found to be strongly expressed in the kidney,<sup>41</sup> and a correlation between *MECOM* and kidney development has been established in different animal models: *Mecom* has a pivotal role in *Xenopus* and zebrafish nephrogenesis<sup>24,42</sup> and is expressed in the urinary system of embryonic mice.<sup>43</sup> However, no phenotype in the renal or urinary system has been reported from various mice knockout models.<sup>35</sup>

Although congenital heart defects are not rare, the frequency of heart defects in our patient group and in the previously reported patients as well as the similarity to the congenital heart defects observed in mice carrying a hypomorphic *Evi1* allele resulting from a deletion of exon 3<sup>44</sup> argue in favor of the causative involvement of the *MECOM* mutation in this phenotype.

Sensorineural deafness was reported for 1 of the patients with *RUSAT* with *HOXA11* variants<sup>5</sup> as well as for patients with *MECOM* mutations.<sup>6,8</sup> Deafness was observed in 3 patients in this study (P2, P10, P12), confirming the association of deafness with RUS and BMF in this disease. Deafness does not seem to be related to an increased susceptibility to otitis media, as described for mice with a dominant missense change in the C-terminal zinc finger region of Mecom.<sup>38</sup> A middle ear bone dysplasia observed in 1 family with *MECOM* mutations<sup>8</sup> could provide a hint regarding the pathomechanism of deafness in MECOM-associated syndrome.

From the synopsis of phenotypic, genotypic, and family analyses, public databases, and prediction algorithms, we conclude that *MECOM* mutations were causative of BMF syndrome in patients P1



to P12. The incomplete penetrance of certain phenotypes, even within families 1 and 2, may be explained either by stochastic factors modulating gene expression<sup>45</sup> or by di- or oligogenic inheritance (eg, joint effects of rare and common variants<sup>46</sup>). Revertant mosaicism also cannot be excluded in family members with no hematological phenotype or in patients with amelioration of BMF.<sup>47</sup> Additional studies are necessary to prove a possible impact of rare sequence variations with uncertain significance (P13-P15, P19, P20) in the pathogenicity of BMF.

On the basis of the phenotypic data from the patients in this and recent reports,<sup>6,9,20,36,37</sup> we conclude that heterozygous *MECOM* mutations or haploinsufficiency of *MECOM* resulting from micro-deletions cause a syndromic disease with a variable phenotypic pattern, varying from severe BMF with multiple organ manifestations to isolated RUS without additional manifestations. Although RUS and BMF are the most common manifestations, none of these symptoms are mandatory for diagnosis of a *MECOM*-associated syndrome. The phenotypic spectrum overlaps with that described for *HOXA11*-associated RUSAT. Both disease patterns include families with dominant inheritance of RUS and variable expression of a hematological phenotype and patients with clinodactyly, presenile hearing loss, and amelioration of thrombocytopenia in the first weeks of life. There are some hints of genotype-phenotype correlations; for example, the phenotype of RUS and B-cell lymphopenia has been observed only in patients with mutations in a small region of the eighth and ninth zinc fingers. However, we found large variations in the phenotypes caused by similar mutations. Major phenotypic differences existed within families (eg, P1 and P2), and in 2 of our patients without RUS, we found a *MECOM* mutation identical to that previously described for 3 patients with RUSAT2.<sup>6,7,9</sup> Other genetic or epigenetic factors presumably influence the phenotypic characteristics.

To include the different manifestations of the disease, namely BMF, RUS, and other skeletal anomalies of the forearms and hands, B-cell deficiency, renal malformations, and presenile hearing loss, we

propose the term *MECOM*-associated syndrome. This definition would also include the BMF observed in patients with haploinsufficiency of *MECOM* resulting from 3q26 deletions.<sup>20,36,37</sup> *MECOM* mutations should be taken into account as a cause of AT or congenital aplastic anemia even if RUS has not been established.

## Acknowledgments

The authors thank all patients and families who participated in this study and the referring physicians. They also acknowledge the excellent technical assistance of Yvonne Peter and Christina Struckmann.

This work was supported in part by grants of the Federal Ministry of Education and Research (German Network on Congenital Bone Marrow Failure Syndromes) and by the transnational ERA-NET funding European Platelet Network (EUPLANE). The study was supported by the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children, NHS Foundation Trust, and University College London.

## Authorship

Contribution: M.G. and M.B. designed and performed research, analyzed data, and wrote the manuscript; P.A., J.E., M.M., E.P., H.R., D.S., R.H.S., S.U., A.W., and B.Z. provided patients' material and data, suggested experiments, and analyzed data; and all authors read, revised, and approved the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Manuela Germeshausen, Central Research Facility Cell Sorting, Medizinische Hochschule Hannover, Carl-Neuberg-Str 1, 30625 Hannover, Germany; e-mail: germeshausen.manuela@mh-hannover.de; and Matthias Ballmaier, Central Research Facility Cell Sorting, Medizinische Hochschule Hannover, Carl-Neuberg-Str 1, 30625 Hannover, Germany; e-mail: ballmaier.matthias@mh-hannover.de.

## References

1. Adam S, Melguizo Sanchis D, El-Kamah G, et al. Concise review: getting to the core of inherited bone marrow failures. *Stem Cells*. 2017;35(2):284-298.
2. Ballmaier M, Germeshausen M, Schulze H, et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. *Blood*. 2001;97(1):139-146.
3. Ballmaier M, Germeshausen M. Advances in the understanding of congenital amegakaryocytic thrombocytopenia. *Br J Haematol*. 2009;146(1):3-16.
4. Thompson AA, Nguyen LT. Amegakaryocytic thrombocytopenia and radio-ulnar synostosis are associated with *HOXA11* mutation. *Nat Genet*. 2000;26(4):397-398.
5. Thompson AA, Woodruff K, Feig SA, Nguyen LT, Schanen NC. Congenital thrombocytopenia and radio-ulnar synostosis: a new familial syndrome. *Br J Haematol*. 2001;113(4):866-870.
6. Niihori T, Ouchi-Uchiyama M, Sasahara Y, et al. Mutations in *MECOM*, encoding oncoprotein *EVI1*, cause radioulnar synostosis with amegakaryocytic thrombocytopenia. *Am J Hum Genet*. 2015;97(6):848-854.
7. Lord SV, Jimenez JE, Kroeger ZA, et al. A *MECOM* variant in an African American child with radioulnar synostosis and thrombocytopenia. *Clin Dysmorphol*. 2018;27(1):9-11.
8. Ripperger T, Hofmann W, Koch JC, et al. *MDS1* and *EVI1* complex locus (*MECOM*): a novel candidate gene for hereditary hematological malignancies. *Haematologica*. 2018;103(2):e55-e58.
9. Bluteau O, Sebert M, Leblanc T, et al. A landscape of germline mutations in a cohort of inherited bone marrow failure patients. *Blood*. 2018;131(7):717-732.
10. Fleischman RA, Letestu R, Mi X, et al. Absence of mutations in the *HoxA10*, *HoxA11* and *HoxD11* nucleotide coding sequences in thrombocytopenia with absent radius syndrome. *Br J Haematol*. 2002;116(2):367-375.

11. Du HY, Pumbo E, Manley P, et al. Complex inheritance pattern of dyskeratosis congenita in two families with 2 different mutations in the telomerase reverse transcriptase gene. *Blood*. 2008;111(3):1128-1130.
12. Richards S, Aziz N, Bale S, et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17(5):405-424.
13. Kleinberger J, Maloney KA, Pollin TI, Jeng LJ. An openly available online tool for implementing the ACMG/AMP standards and guidelines for the interpretation of sequence variants. *Genet Med*. 2016;18(11):1165.
14. Choi Y, Chan AP. PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. *Bioinformatics*. 2015;31(16):2745-2747.
15. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc*. 2009;4(7):1073-1081.
16. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. *Nat Methods*. 2010;7(4):248-249.
17. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. *Nat Methods*. 2014;11(4):361-362.
18. Ballmaier M, Holter W, Germeshausen M. Flow cytometric detection of MPL (CD110) as a diagnostic tool for differentiation of congenital thrombocytopenias. *Haematologica*. 2015;100(9):e341-e344.
19. Buonamici S, Li D, Chi Y, et al. EVI1 induces myelodysplastic syndrome in mice. *J Clin Invest*. 2004;114(5):713-719.
20. Nielsen M, Vermont CL, Aten E, et al. Deletion of the 3q26 region including the EVI1 and MDS1 genes in a neonate with congenital thrombocytopenia and subsequent aplastic anaemia. *J Med Genet*. 2012;49(9):598-600.
21. Staba SL, Sola MC, William SB. Unrelated donor umbilical cord blood transplantation in two children with amegakaryocytic thrombocytopenia with radio-ular synostosis [abstract]. *Biol Blood Marrow Transplant*. 2006;12(2 Suppl 1):129-130. Abstract 373.
22. Yoshida H, Hashii Y, Okuda T, et al. A case of congenital bone marrow failure with radio-ular synostosis. *Int J Hematol*. 2010;91(2):331-332.
23. Dokal I, Ganly P, Riebero I, et al. Late onset bone marrow failure associated with proximal fusion of radius and ulna: a new syndrome. *Br J Haematol*. 1989;71(2):277-280.
24. Li Y, Cheng CN, Verdun VA, Wingert RA. Zebrafish nephrogenesis is regulated by interactions between retinoic acid, mecom, and Notch signaling. *Dev Biol*. 2014;386(1):111-122.
25. Mead PE, Parganas E, Ohtsuka S, et al. Evi-1 expression in *Xenopus*. *Gene Expr Patterns*. 2005;5(5):601-608.
26. Yuasa H, Oike Y, Iwama A, et al. Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. *EMBO J*. 2005;24(11):1976-1987.
27. Kataoka K, Sato T, Yoshimi A, et al. Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity. *J Exp Med*. 2011;208(12):2403-2416.
28. Goyama S, Yamamoto G, Shimabe M, et al. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. *Cell Stem Cell*. 2008;3(2):207-220.
29. Kustikova OS, Schwarzer A, Stahlhut M, et al. Activation of Evi1 inhibits cell cycle progression and differentiation of hematopoietic progenitor cells. *Leukemia*. 2013;27(5):1127-1138.
30. Wieser R. The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. *Gene*. 2007;396(2):346-357.
31. Hinai AA, Valk PJ. Review: Aberrant EVI1 expression in acute myeloid leukaemia. *Br J Haematol*. 2016;172(6):870-878.
32. Nishikawa S, Arai S, Masamoto Y, et al. Thrombopoietin/MPL signaling confers growth and survival capacity to CD41-positive cells in a mouse model of Evi1 leukemia. *Blood*. 2014;124(24):3587-3596.
33. Germeshausen M, Ballmaier M, Welte K. MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease. *Hum Mutat*. 2006;27(3):296.
34. Simmons BP, Southmayd WW, Riseborough EJ. Congenital radioulnar synostosis. *J Hand Surg Am*. 1983;8(6):829-838.
35. Blake JA, Eppig JT, Kadin JA, Richardson JE, Smith CL, Bult CJ; the Mouse Genome Database Group. Mouse Genome Database (MGD)-2017: community knowledge resource for the laboratory mouse. *Nucleic Acids Res*. 2017;45(D1):D723-D729.
36. Bouman A, Knecht L, Gröschel S, et al. Congenital thrombocytopenia in a neonate with an interstitial microdeletion of 3q26.2q26.31. *Am J Med Genet A*. 2016;170A(2):504-509.
37. van der Veken LT, Maiburg MC, Groenendaal F, et al. Lethal neonatal bone marrow failure syndrome with multiple congenital abnormalities including limb defects due to a constitutional deletion of 3' MECOM [published online ahead of print 8 February 2018]. *Haematologica*. doi:10.3324/haematol.2017.185033.
38. Parkinson N, Hardisty-Hughes RE, Tateossian H, et al. Mutation at the Evi1 locus in Junbo mice causes susceptibility to otitis media. *PLoS Genet*. 2006;2(10):e149.
39. Cornet E, Mossafa H, Courel K, Lesesve JF, Troussard X. Persistent polyclonal binucleated B-cell lymphocytosis and MECOM gene amplification. *BMC Res Notes*. 2016;9:138.
40. Li BE, Gan T, Meyerson M, Rabbitts TH, Ernst P. Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells. *Blood*. 2013;122(12):2039-2046.

41. Morishita K, Parganas E, Parham DM, Matsugi T, Ihle JN. The Evi-1 zinc finger myeloid transforming gene is normally expressed in the kidney and in developing oocytes. *Oncogene*. 1990;5(9):1419-1423.
42. Van Campenhout C, Nichane M, Antoniou A, et al. Evi1 is specifically expressed in the distal tubule and duct of the *Xenopus* pronephros and plays a role in its formation. *Dev Biol*. 2006;294(1):203-219.
43. Perkins AS, Mercer JA, Jenkins NA, Copeland NG. Patterns of Evi-1 expression in embryonic and adult tissues suggest that Evi-1 plays an important regulatory role in mouse development. *Development*. 1991;111(2):479-487.
44. Bard-Chapeau EA, Szumska D, Jacob B, et al. Mice carrying a hypomorphic Evi1 allele are embryonic viable but exhibit severe congenital heart defects. *PLoS One*. 2014;9(2):e89397.
45. Raj A, van Oudenaarden A. Nature, nurture, or chance: stochastic gene expression and its consequences. *Cell*. 2008;135(2):216-226.
46. Gibson G. Rare and common variants: twenty arguments. *Nat Rev Genet*. 2012;13(2):135-145.
47. Osumi T, Tsujimoto SI, Nakabayashi K, et al. Somatic MECOM mosaicism in a patient with congenital bone marrow failure without a radial abnormality [published online ahead of print 22 January 2018]. *Pediatr Blood Cancer*. doi:10.1002/pbc.26959.
48. Dogan H, Can H, Otu HH. Whole genome sequence of a Turkish individual. *PLoS One*. 2014;9(1):e85233.
49. Schatorjé EJ, Gemen EF, Driessen GJ, et al. Age-matched reference values for B-lymphocyte subpopulations and CVID classifications in children. *Scand J Immunol*. 2011;74(5):502-510.
50. Huenecke S, Behl M, Fadler C, et al. Age-matched lymphocyte subpopulation reference values in childhood and adolescence: application of exponential regression analysis. *Eur J Haematol*. 2008;80(6):532-539.